Dashboard
Poor long term growth as Operating profit has grown by an annual rate 12.55% of over the last 5 years
Flat results in Jul 25
With ROCE of 7.05%, it has a expensive valuation with a 1.60 Enterprise value to Capital Employed
High Institutional Holdings at 100%
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 13,979 Million (Small Cap)
36.00
NA
0.00%
0.28
4.88%
1.67
Total Returns (Price + Dividend) 
The Cooper Cos., Inc. for the last several years.
Risk Adjusted Returns v/s 
News

The Cooper Companies Experiences Revision in Stock Evaluation Amid Market Dynamics
The Cooper Companies, Inc. has recently revised its evaluation amid market fluctuations, with its stock priced at $77.93. Over the past year, it has seen significant volatility, with a high of $106.63 and a low of $61.77. The company's performance contrasts with the S&P 500, showing mixed returns.
Read MoreIs The Cooper Cos., Inc. overvalued or undervalued?
As of 7 November 2025, the valuation grade for The Cooper Cos., Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still suggesting overvaluation. The company is considered overvalued based on its P/E ratio of 36, which is significantly higher than peers such as Hologic, Inc. with a P/E of 21.83 and Align Technology, Inc. at 20.46. Additionally, the EV to EBITDA ratio stands at 15.35, which is also elevated compared to the industry average. The Cooper Cos., Inc. shows a PEG ratio of 1.69, further highlighting its expensive valuation relative to growth expectations. The return comparison reveals that the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -23.07% compared to the S&P 500's 14.40%. This trend reinforces the notion that the stock is overvalued in the current market context....
Read More
The Cooper Companies Experiences Revision in Its Stock Evaluation Amid Market Challenges
The Cooper Companies, Inc. has recently adjusted its valuation, with a current P/E ratio of 36 and a price-to-book value of 1.78. The company has faced performance challenges, showing a year-to-date return of -23.75% and a decline of 32.16% over the past year, compared to the S&P 500.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Apr 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 132 Schemes (45.86%)
Held by 353 Foreign Institutions (27.24%)
Quarterly Results Snapshot (Consolidated) - Jul'25 - QoQ
QoQ Growth in quarter ended Jul 2025 is 5.79% vs 3.90% in Apr 2025
QoQ Growth in quarter ended Jul 2025 is 12.09% vs -15.92% in Apr 2025
Annual Results Snapshot (Consolidated) - Oct'24
YoY Growth in year ended Oct 2024 is 8.41% vs 8.61% in Oct 2023
YoY Growth in year ended Oct 2024 is 33.34% vs -23.74% in Oct 2023






